Results 81 to 90 of about 13,040 (222)

Short-term recurrent coronary artery thrombosis with acute myocardial infarction in a patient with aplastic anemia–paroxysmal nocturnal hemoglobinuria syndrome: a case report

Frontiers in Cardiovascular Medicine
BackgroundAcute myocardial infarction commonly occurs in patients with coronary artery disease, but rarely, it can develop under a hypercoagulable state.
Xue-Guo Fu, Yan-Hua Guo, Shi-Chao Wang, Wen-Quan Zhang   +3 more
doaj   +1 more source

Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature

Haematologica, 2012
Background Thrombosis is the major risk factor for death in patients with paroxysmal nocturnal hemoglobinuria. Previous case reports indicate that venous thrombosis in patients with paroxysmal nocturnal hemoglobinuria is amenable to thrombolysis.Design ...
David J. Araten, Rosario Notaro, Howard T Thaler, Nancy Kernan, Farid Boulad, Hugo Castro-Malaspina, Trudy Small, Andromachi Scaradavou, Heather Magnan, Susan Prockop, Sara Chaffee, Jason Gonsky, Raymond Thertulien, Roberto Tarquini, Lucio Luzzatto   +14 more
doaj   +1 more source

Methemoglobinemia without hemolytic anemia following exposure to naphthalene moth balls

Journal of Pediatric Critical Care, 2019
Mothballs are commonly used household product that contain an aromatic hydrocarbon named naphthalene. On systemic exposure it causes oxidant injury to hemoglobin molecules resulting in oxidized forms of hemoglobin like methaemoglobin and further ...
Snehamayee Nayak, Jyotiranjan Satpathy, Bijaylaxmi Mallick, Mangal Charan Murmu   +3 more
doaj   +1 more source

Post-Partum Hemoglobinuria (PPH) in Bovine

<p><span>Post-partum hemoglobinuria (PPH) is commonly known as “Lahu mutna” or “Rakth mutna” in field condition. PPH is a metabolic disease of high yielding cows and buffaloes, usually occurs within 30 days of calving.
Manju Bissu*, 1Priyanka Bissu (PG Scholar) and 2Sandeep Bissu
core   +1 more source

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1303-1304, June 2026.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

Haematologica, 2014
Complement blockade by eculizumab is clinically effective in hemolytic paroxysmal nocturnal hemoglobinuria. However, the response is variable and some patients remain dependent on red blood cell transfusions.
Tommaso Rondelli, Antonio M. Risitano, Régis Peffault de Latour, Michela Sica, Benedetta Peruzzi, Patrizia Ricci, Wilma Barcellini, Anna Paola Iori, Carla Boschetti, Veronica Valle, Veronique Frémeaux-Bacchi, Maria De Angioletti, Gerard Socie, Lucio Luzzatto, Rosario Notaro   +14 more
doaj   +1 more source

Measurement of Active Thrombin Bound to Circulating D‐Dimers as a Sensitive Biomarker for Prothrombotic Conditions

Journal of Clinical Laboratory Analysis, Volume 40, Issue 11, June 2026.
Scheme of preparation of D‐dimers and evaluation of D‐dimer‐bound thrombin activity. Thrombin bound to fibrin participates in ongoing fibrinogen transformation and its inhibition is impeded. Our detection system may aid in identifying patients at risk of recurrent thrombotic events or complications, regardless of the origin of the acute health problem.
Jana Stikarova, Leona Chrastinova, Kristyna Svobodova, Marek Havlicek, Jan Louzil, Eliska Ceznerova, Alzbeta Hlavackova, Ondrej Pastva, Pavla Pecherkova, Ingrid Hrachovinova, Ondrej Kucerka, Roman Kotlin, Petr Soukup, Peter Salaj, Martin Maly, Jiri Suttnar   +15 more
wiley   +1 more source

Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post‐Marketing Surveillance Sub‐Analysis

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Thrombotic events (TEs) account for approximately 40%–67% of deaths in untreated paroxysmal nocturnal haemoglobinuria (PNH). C5 inhibitor treatment (e.g., eculizumab and ravulizumab) greatly reduces the incidence of TEs in patients with PNH, but data on the characteristics of PNH patients experiencing TEs are limited.
Takayuki Ikezoe, Tatsuya Kawaguchi, Hideo Hayashi, Akihiko Shimono, Jun‐ichi Nishimura   +4 more
wiley   +1 more source

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations

, 2016
Fatimah Al-Ani,1 Ian Chin-Yee,1 Alejandro Lazo-Langner1,2 1Department of Medicine, Division of Hematology, 2Department of Epidemiology and Biostatistics, Western University, London, ON, Canada Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a ...
Chin-Yee I, Lazo-Langner A, Al-Ani F
core  

Off-Pump Coronary Revascularization Using Bilateral Internal Thoracic Arteries in A Patient with Paroxysmal Nocturnal Hemoglobinuria: A Case Report

Brazilian Journal of Cardiovascular Surgery
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-orphan disease. We report the first case in the literature of Off-Pump Coronary Revascularization Using Bilateral Internal Thoracic Arteries in a patient with paroxysmal nocturnal hemoglobinuria. A 36-
Juan Mariano Vrancic, Manuel Roque Cervetti, Julián Benavides, Daniel Navia   +3 more
doaj   +1 more source